clinical trial · NCT06459869
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
Akamis Bio·phase1·recruiting·n = 30
Locally Advanced Rectal Cancer (LARC)NG-350A IV administrationCapecitabine oral administrationRadiotherapy
brief summary
The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.
started
Apr 7, 2025
primary completion
Nov 30, 2026
completion
Nov 30, 2028
last updated
Feb 17, 2026
official title
A Multicentre, Open-label, Non-randomized, Phase 1b Trial of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Chemoradiotherapy in Locally Advanced Rectal Cancer (FORTRESS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol